Hudson, WI, United States of America

William E Coyne

This inventor holds 1 USPTO granted patent. Top assignee: Riker Laboratories Inc.. Active years: 1978.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 1978

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of William E. Coyne

Introduction

William E. Coyne is an accomplished inventor based in Hudson, WI (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of antiarrhythmic agents. His work has implications for the treatment of heart conditions, showcasing the importance of innovation in medical science.

Latest Patents

William E. Coyne holds a patent for "Tertiary amide derivatives of pyrrolidine and piperidine." This patent describes certain compounds in which a carbon atom of a pyrrolidine or piperidine ring is bonded directly or through a methylene group to the completely substituted nitrogen of a substituted benzamido group. These compounds, along with their pharmaceutically acceptable salts, are recognized as active antiarrhythmic agents. He has 1 patent to his name.

Career Highlights

Coyne's career is marked by his dedication to research and development in the pharmaceutical industry. He works at Riker Laboratories Inc., where he collaborates with other professionals to advance medical science. His innovative approach has led to the creation of compounds that can significantly impact patient care.

Collaborations

One of his notable coworkers is Elden H. Banitt. Together, they contribute to the research and development efforts at Riker Laboratories Inc., fostering an environment of innovation and collaboration.

Conclusion

William E. Coyne's work exemplifies the vital role of inventors in advancing healthcare through innovative solutions. His contributions to the field of antiarrhythmic agents highlight the importance of continued research and development in pharmaceuticals.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…